Ocean Biomedical Inc., a company with preclinical programs in oncology, fibrosis, infectious disease treatments and vaccines, is poised to go public via a merger with Aesther Healthcare Acquisition Corp., a special purpose acquisition company (SPAC).
Astrivax BV has raised €30 million (US$30.1 million) in a seed round to take forward the development of a novel vaccine technology that combines a plasmid vector with a replication-competent virus.
Australian radiopharmaceutical company Advancell Co. Ltd. closed an AU$18 million (US$12.4 million) series B round that will take its lead targeted alpha-emitting radiotherapy, ADVC-001, for metastatic prostate cancer to the clinic by the end of 2022.
3T Biosciences Inc. raised $40 million in a series A funding round to take forward a platform for identifying novel T-cell receptors (TCR) and their targets, which is based on the work of scientific co-founder K. Christopher Garcia of Stanford University.
Biopharmas raising money in public or private financings, including: Advancell, Bright Minds, Freedom, Regenacy, Relief, Sanotize, Shuttle, Third Harmonic.
Etherna Immunotherapies NV has raised €39 million (US$39 million) in new financing as it pivots to an mRNA-platform strategy. It has added a couple of heavy hitters to its board and its roster of investors, indicating that the move has already gained traction in the marketplace.
RSS
